Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

All Conditions

Immune System Diseases

Symptoms and General Pathology

Diabetes Mellitus

Diabetes Mellitus, Type 1

Necrosis

Metabolic Diseases

Glucose Metabolism Disorders

Endocrine System Diseases

Autoimmune Diseases

All Drugs and Chemicals

Anti-Infective Agents

Antineoplastic Agents

Anti-Inflammatory Agents

Antirheumatic Agents

Analgesics

Gastrointestinal Agents

Central Nervous System Depressants

Hypoglycemic Agents

Anti-Obesity Agents

Other Dietary Supplements

Tacrolimus

Sirolimus

Etanercept

Basiliximab

Benzocaine

Exenatide

Daclizumab

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Immunosuppressive Agents

Immunologic Factors

Glucagon

Glucagon-Like Peptide-1 Receptor Agonists

Glucagon-Like Peptide 1

Incretins

Hormones

Hormone Antagonists

Tannic Acid

1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.

1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.

1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml

Islet Cell Transplant

1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.

Islet Cell Transplant plus

Jose Oberholzer, MD

The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC). The purpose is to reproduce the Edmonton protocol to demonstrate that pancreatic islets isolated at UIC are safe and of sufficient quality to provide reproducible graft function.

Diabetes mellitus is becoming an unbearable burden for the health care system worldwide. The incidence of disease has increased over the past 50 years, both for type I and type II diabetes. In 2002, the expenditure for direct and indirect costs of diabetes reached the astronomical amount of $132 billion for the USA alone. The burden suffered by patients is also grave when we consider that diabetic neuropathy and retinopathy are now the leading causes of renal failure and blindness in industrialized countries. Although major improvements in insulin treatment and glycemic control have been achieved, the development of hypoglycemic unawareness still represents a challenging clinical problem in the management of diabetes. Severe hypoglycemic episodes are not only acutely life threatening but lead to overall impairment of the quality of life of diabetic patients. Even under ideal study conditions the pathophysiology of hypoglycemic unawareness is not fully understood. It seems that each hypoglycemic episode reduces the counterregulatory hormone responses and the subjective awareness of the following episode, generating a self-worsening mechanism. Islet transplantation can effectively eliminate severe hypoglycemia and restore good glycemic control. However, there are still several limitations to the widespread application of islet transplantation. First, insulin independence is mostly achieved by transplanting a high number of islets that are harvested from 2-4 donors. Second, post-transplant insulin-independence is progressively lost over time despite continued endogenous insulin secretion. Lastly, current immunosuppression carries potential risks and can only incompletely prevent sensitization of the host and rejection.

At present, clinical trials in islet transplantation face stringent federal regulations, which define islets as a biological drug and islet transplantation as an experimental procedure. Limited resources impose small and uncontrolled trials investigating a limited number of new interventions to improve outcomes.

This study is a Phase 1/2 single center, uncontrolled trial in which 1-3 allogeneic pancreatic islet transplants are performed for each study subject. Post-transplant follow-up continues for 64 weeks after the final islet transplantation. Thereafter, subjects are enrolled for a 5-year follow-up study and a 5 to 10 year follow-up study.

The safety of islet transplantation depends primarily on the incidence of serious and unexpected complications or adverse events and the ability of the cell isolation laboratory to produce uncontaminated islet cell preparations with minimal endotoxin content. All study subjects are followed for safety for one year. An independent Data Monitoring Committee (DMC), composed of 3 members who have training in medicine and/or organ transplantation, will review eligibility and safety data approximately 2 weeks after each islet transplantation and every two months thereafter. An independent monitor knowledge on Good Clinical Practice(GCP) guidelines and regulations monitors the study for compliance with 21 CFR and according to ICH GCP Guidelines. Within the Clinical Research Center, the Scientific Advisory Committee and the Research Subject Advocacy Program monitor safety. These entities report to the Institutional Review Board, which also reviews safety data annually and on occurrence of serious adverse events. The principal investigator also report serious adverse events to the US Food and Drug Administration (FDA).

Success: Islet transplantation is considered a success when subjects do not use insulin and they achieve a fasting glucose level not exceeding 140 mg/dL more than three times in a week, and not exceeding two-hour post-prandial values of 180 mg/dL more than four times in a week.

Partial Success: Subjects who have a reduction in insulin requirements but who do not achieve insulin independence and present with a reduction in HbA1c and number of hypoglycemic episodes are considered to have partial success of islet transplantation. Reduction in insulin-requirements are assessed by comparing the pre-transplant insulin requirement recorded over two consecutive days (expressed as insulin units per kg) with the requirement on the two consecutive days preceding the subsequent islet infusion, and the requirements on two consecutive days at six months and again on two consecutive days at one year after the final transplant.

Failure: Absence of measurable levels of C-peptide after transplantation is considered as failure of islet cell transplantation.

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

* Frequency of adverse events including laboratory abnormalities
* HbA1C (less than 6.1% is considered normal)
* Glucose control and absence of hypoglycemic coma/unawareness, as evidenced by no further requirement for third-party assistance or hospital attendance resulting from a severe hypoglycemic episode
* Renal function, measured both by serum creatinine and calculated GFR using the Cockroft \& Gault
* Lipid profiles for cholesterol, triglycerides, low density lipoprotein (LDL) and high density lipoprotein (HDL)
* PRA
* Doppler ultrasound to exclude or document portal vein thrombosis
* Immunosuppressive drug trough levels
* Renal clearance (GFR)
* Liver function tests
* Diagnosis of opportunistic infections, e.g., CMV

Primary efficacy outcome: independence from insulin injections with adequate control of blood glucose in subjects with Type 1 diabetes. Transplant is considered a success when 2 weeks after their last transplant, subjects are not using insulin, and fasting glucose levels do not exceed 7.8 mmol/L (140 mg/dL) more than 3 times/week, and two-hour post-prandial glucose values do not exceed 10 mmol/L (180 mg/dL) more than 4 times/week. During the 15 months after last transplant, a subject will be considered a success if an illness or other event (e.g., high tacrolimus level) causes need for insulin not exceeding 14 days providing evidence of graft rejection is not apparent. The proportion of subjects who are insulin independent and meet criteria for glucose control will be determined at 2 weeks and 1, 3, 6, 12, and 15 months following their final islet transplant.

HbA1c less than or equal to 6.5 at end of 15 month study participation, and lack of or free from severe hypoglycemic events, defined as an event with symptoms compatible with hypoglycemia in which the subject required the assistance of another person and which was associated with either a blood glucose level \< 50 mg/dl (2.8 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.

University of Illinois at Chicago

Professor, Division of Transplantation

Review of Systems and adverse events at each study visit, physical examinations, notification from subjects.

Islet Cells

Islet Cells + Etanercept + Exenatide

Islet transplantation and the Edmonton protocol of steroid free immunosuppression

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

The number of participants analyzed represents the number of subjects in Group 1 (Islet Cells) and Group 2 (Islet Cells + Etanercept + Exenatide)

Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation

Number of Participants With Insulin Independence at End of Study Participation

Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Events

Group 1 (Islet Cells)

Group 2 (Islet Cells + Etanercept + Exenatide)

Overall Study

Spots Global Cancer Trial Database for soluble tumor necrosis factor receptor